Download National Cancer Center Introductory Overview

Overview
February 2017
National Cancer Center

Established in 1962 by Ministry of Health and Welfare
(MHLW*1) as the first National Center for Advanced and
Specialized Medical Care among 6 National Centers

Leadership role in nation-wide cancer practice, research
and education

Shifted to “Independent Administrative Institute*2” on April
1, 2010

Appointed as “National Research and Development
Agency*3” on April 1, 2015
*1MHLW: current Ministry of Health, Labour and Welfare
*2Privatized Government Corporation, *3Highest Ranked Research Organization
2
National Cancer Center Milestones
1962
Jan
National Cancer Center establishes
History of Cancer Control
1962
May
Hospital starts operating
1964 National Strategy: Five Pillars of
Cancer Control
1992
Jul
NCC Hospital East establishes
2004
Feb
Research Center for Cancer Prevention and
Screening establishes
2005
Oct
Research Center on Innovative Oncology
establishes
2006
Oct
Center for Cancer Control and Information
Services establishes
2005 Action Plan 2005
2007 Basic Plan to Promote Cancer
Control
2010
Apr
Shifts to Independent Administrative
Institution
2012
Sep
Exploratory Oncology Research & Clinical
Trial Center establishes
2016
Jan
Center for Research Administration and
Support/ Center for Cancer Registries
establishes
1984 Comprehensive Ten-year Strategy
for Cancer Control
1994 New Ten-year Strategy to
Overcome Cancer
2004 The 3rd-term Comprehensive Tenyear Strategy for Cancer Control
2006 Cancer Control Act
2012 Basic Plan to Promote Cancer
Control (Revised)
201410-year Strategy of Cancer
Research
2015 AMED starts
Japan Cancer Research Project
3
3
Vision and Mission of National Cancer Center
NCC aims for:
Not to get cancer, not to be defeated by cancer, live with cancer
Vision
NCC is committed to providing the best possible cancer treatment and care through relentless
partnership with the community
Missions
1.
Discovering the fundamental causes of cancer and realizing its earliest diagnosis and prevention
2.
Developing innovation in medical prevention, diagnosis and treatment
3.
Establishing and making available the most advanced standard of care to all patients
4.
Exploring and providing the best “cancer survivorship” for patients
5.
Gathering and disseminating comprehensive cancer related information to the community
6.
Talent development of all NCC staff members
7.
Recommending new initiatives and policy to the government
8.
Contributing to global society in collaboration with international organizations
Slogans:
Novel, Challenge and Change
All Activities for Cancer Patients!
4
組 織 図 Cancer Center
Organization of National
Board of Directors
President of NCC
Auditors
Directors’ Meeting
Executive Advisers to President
Number of Staff: 3092
(as of Apr. 1, 2016)
Strategic Planning Bureau
Center for Research
Administration and Support
Center for Education and
Professional Career Development
Office for Advanced Medical Care Evaluation
and Health Technology Assessment
Hospital, Tsukiji campus
Hospital East, Kashiwa campus
Research Institute
Exploratory Oncology
Research & Clinical Trial Center
Center for Public Health Sciences
Center for Cancer Control
and Information Services
Administrative Departments
Audit office
5
Hospital
Director
(as of July 1, 2016)
in Tsukiji Campus
Deputy Directors





Clinical Management
Education
Research
Safety Management
Development and Planning
Office of Safety
Management
Office of Infection
Control & Prevention
Common Departments
‐Outpatient Treatment Center
‐Endoscopy Center
‐Consultation, Counseling and
Support Service Center
‐Appearance Support Center
‐Rare Cancer Center
‐Interventional Radiology Center
‐Supportive Care Development Center
‐Genetic Medicine and Services
‐Innovation Center for Supportive, Palliative and
Psychosocial Care
‐Screening Center
‐Clinical Laboratories
‐Surgical Center
‐Clinical Engineering and Medical Technology
‐Physician Referral Service Office
‐Nutrition Management Office
‐Health Information Management Office
‐Pharmacy
‐Nursing
‐Department of Radiological Technology
‐Clinical Research Support Office
Clinical Departments
‐Neurosurgery and
Neuro-Oncology
‐Ophthalmic Oncology
‐Head and Neck Surgery
‐Plastic and Reconstructive
Surgery
‐Breast Surgery
‐Breast and Medical Oncology
‐Thoracic Surgery
‐Thoracic Oncology
‐Esophageal Surgery
‐Gastric Surgery
‐Colorectal Surgery
‐Gastrointestinal Medical
Oncology
‐Endoscopy
‐Hepatobiliary and Pancreatic
Surgery
‐Hepatobiliary and Pancreatic
Oncology
‐Urology
‐Gynecology
‐Musculoskeletal Oncology and
Rehabilitation
‐Dermatologic Oncology
‐Hematology
‐Hematopoietic Stem Cell
Transplantation
‐Blood Transfusion and Cellular
Therapy
‐Pediatric Oncology
‐Pediatric Surgery
‐General Internal Medicine, Dentistry,
Oncologic Emergency
‐Anesthesia and Intensive Care
‐Palliative Medicine
‐Psycho-Oncology
‐Diagnostic Radiology
‐Radiation Oncology
‐Pathology and Clinical Laboratories
‐Experimental Therapeutics
6
Hospital
in Tsukiji Campus
578 beds
178 Staff Drs, 134 Resident Drs
587 Nurses
as of April 1, 2016
Out-patient



Approx. 1300 patients per day for new and return patients
Out-patient treatment center has 62 beds, providing chemotherapy
to approx. 130 patients per day
High precision radiation therapy
In-Patient






17 operation rooms; approx.5400 operations per year
Advanced endoscopic surgery for early gastric cancer (endoscopic
mucosal resection or endoscopic submucosal dissection<ESD>)
Cutting-edge Interventional radiology with 2 Angio-CT systems
Hematopoietic Stem Cell Transplant
Palliative Medication and Patient Support
Hospital based clinical trials and researches
Cyber Knife
Cancer Screening Services


High-precision screening using spiral-CT, positron emission
tomography (PET), etc.
3,000 screening tests per year
Rare cancer hot-line
Out-patient Treatment
Appearance Support Center
Endoscopy therapeutic room
Built-in wiring ceiling system
Daily tips for patients
7
Hospital East
Director
Common Departments
‐Rare Cancer Center
‐Outpatient Treatment Center
‐Clinical Laboratories
‐Surgical Center
‐Supportive Care Center
‐Radiation Safety and Quality
Assurance
‐Nutrition Management Office
‐Office of Cancer Registry
‐Medical Information Management Office
‐Medical Information
‐Pharmacy
‐Nursing
‐Radiological Technology
‐Clinical Research Support Office
‐Certified Nurse Curriculum
‐Genetic Medicine and Services
(as of July 1, 2016)
in Kashiwa campus
Deputy Directors




Clinical Management
Education
Research
Safety Management
Office of Safety
Management
Clinical Departments
‐Head and Neck Surgery
‐Head and Neck Medical
Oncology
‐Plastic and Reconstructive Surgery
‐Breast Surgery
‐Breast and Medical Oncology
‐Thoracic Surgery
‐Thoracic Oncology
‐Esophageal Surgery
‐Gastric Surgery
‐Colorectal Surgery
‐Gastrointestinal Oncology
‐Digestive Endoscopy
‐Hepatobiliary and
Pancreatic Surgery
‐Hepatobiliary and
Pancreatic Oncology
‐Urology
‐Gynecology
‐Musculoskeletal Oncology and
Rehabilitation
‐Hematology
‐General Internal Medicine,
Dentistry, Cardiovascular
Medicine, Pediatric Oncology
‐Anesthesiology
‐Intensive Care Service
‐Palliative Medicine,
Palliative Care Service
‐Psycho-Oncology Service
‐Diagnostic Radiology
‐Radiation Oncology
‐Pathology and
Clinical Laboratories
‐Experimental Therapeutics
8
Hospital East
in Kashiwa campus 425 beds （including 25 beds for palliative care)
95 Staff Doctors, 88 Resident Doctors
445 Nurses
as of April 1, 2016
What’s different?

Proton Treatment Facility


Supportive Care Center


Support patients and their families physically, mentally, socially, and spiritually
Early Stage Clinical Development


Assist patients for both treatment and daily life from early stage
First Palliative Care Ward among national hospitals


First in Japan & Second in the world in-hospital treatment facility
Abundant experience in early clinical trials and translational research
Minimally invasive surgeries

ESD, Laparoscopic surgeries
Proton Treatment Facility
Supportive care center
Palliative care wards
9
(as of July 13, 2016)
Research Institute
Director
Deputy Director
Fundamental Innovative
Oncology Core
Cancer Development
and Progression
Translational
Research
‐Molecular Pathology
‐Chemotherapy and Clinical
‐Genetics
Research
‐Carcinogenesis and Prevention ‐Cancer Pathophysiology
‐Cancer Biology
‐Molecular and Cellular Medicine
Research of Molecular
Functions and Targets
‐Hematological Malignancy
‐Cancer Stem Cell
‐Cancer Differentiation
Frontier Science
‐Molecular Pharmacology
‐Rare Cancer Research
‐Refractory and Advanced Cancer
‐Cancer Immunology
‐Molecular Modification and
Cancer Biology
Development of Molecular Diagnostics and
Individualized Therapy
‐Epigenomics
‐Cancer Genomics
‐Genome Biology
‐Brain Tumor Translational Research
Research Support
Core
‐Research Support
‐Central Animal
‐RI Research Support
Bioresources Core
‐Biobank and Tissue Resources
‐Patient-Derived Cell Line and
Xenograft
Clinical Development Research Core
‐Molecular Imaging & Pharmacokinetics
‐Innovative Seeds Evaluation ‐Clinical Genomics
Biomarker and Therapeutic Target Research Core
‐Translational Oncology
‐Analytical Pathology
‐Functional Analysis
Pre-Clinical Research Core (PCR)
‐Animal Experimentation
‐Cell Culture Technology
‐Bioinformatics
‐Omics Network
10
Research Institute

The largest cancer research center in
Japan, with 364 research staff
（including adjuncts, research fellows, visiting fellows,
invited scholars, administrative staff, as of April 1,
2016）
Major Accomplishments
From 1960’s to 1990’s,
 Discovered heterocyclic amines, food-born carcinogens.
 Developed the PCR-SSCP method (cited more than 3,000 times).
 Completed mapping of chromosome 21, and cloned AML1.
Recently,
 Identified novel fusion genes (RET cancer gene) in lung cancers, and
characterized mutations in hepatitis C-associated liver cancers.
 Initiated international collaboration on the epigenetic field for cancerization
including “mechanism of tumor development” and “cancer prevention and
treatment”.
 Developed markers for patient stratification (early diagnosis and new drug
development) in multiple types of cancers from miRNA analysis.
11
Bridge the gap between preclinical to clinical
for efficient drug development
Research Institute
Hospital
EPOC
Hospital East
Fundamental Innovative
Oncology Core
Fundamental Innovative Oncology Core
Support animal &
human biological
experiments
Research Support Core
Development of
first Japanese Clin.
Sequencing lab.
Bioresources Core
Clinical Development
Research Core
Biomaker & Therapeutic
Target Research Core
Pre-Clinical Research Core
Pathology and Clinical
Laboratories
CLIA level
laboratory
< Bioresources core >
・Genomic testable blood / tissue samples
(yr 2013)
Hospital
: 2,928,640
Hospital East: 183,416
・Pathological material with clinical information
Hospital：
3,834 (Operations)
16,370 (Biopsy)
Hospital East： 2,385 (Operations)
9,168 (Biopsy)
•Cell line
•919 cell lines
•Self-made 165 lines
•Animal model
•Transplanted model
•Produce PD x model
•Test tube model
Develop original
phenotype in-vitro
or animal models
Collaboration with
academia or private
companies
12
(as of July 1, 2016)
Exploratory Oncology Research &
Clinical Trial Center (NCC-EPOC)
Director
Innovative Diagnostic &
Therapeutic Device GR
research
Group
Experimental
Therapeutics
Biomarker Discovery
Translational
Genomics
Cancer Immunology
Clinical
Pharmacology & TR
Innovative Pathology
and Laboratory
Medicine
Pathology
Developmental
Pathology
Therapeutics
•
First-in-human trials (FIH)
Investigator-initiated trials (IITs) for
unapproved drugs (including POC clinical
trials)
Translational Research (TR)
Cancer
Immunotherapy
•
•
Psycho-Oncology
Supportive Care
Research
Functional Imaging
Radiation Oncology
and Particle Therapy
Boron Neutron
Capture Therapy
Science and
Technology for
Endoscopy
Surgical Technology
Experimental Animals
Support of Animal
Experimentaion
Mission
Clinical
TR
Group
Innovative Cancer
Treatment GR
History
Jul 2011
NCC was selected as one of the designated early phase
and exploratory clinical trial centers by the Ministry of
Health, Labour and Welfare.
Sep 2012
NCC-EPOC was launched as a virtual organization for the
missions above involving both Kashiwa and Tsukiji
campuses.
Apr 2013
NCC-EPOC became an independent section in NCC with
its own budget.
Apr 2015
Expanded by Integrating Research Center for Innovative
Oncology of East Hospital
13
Exploratory Oncology Research &
Clinical Trial Center (NCC-EPOC)
Active trials
As of March 31, 2015
Seeds from academia
FIH trial
Investigator Initiated
Registration Trial
Preclinical
Phase I
Phase II
8
2
1
24
6
Remarks
NCC, Keio Uni., Cancer Institute Hospital, National
Institute of Biomedical Innovation and others
IIT 3, Domestic companies 14, Inter’l companies 7
6
For approval
Other Expand Access Program (EAP) 3 trials
Academia-Private All Japan genome screening
consortium: SCRUM-JAPAN

Unite LC-SCRUM-Japan for lung cancer (yr 2013-)
& GI-SCREEN for colorectal cancer (yr 2014-）

Conduct genome screening using cutting-edge
pan-cancer panel (ocp) for drug development

Collaboration with 12 domestic and intr’l
Pharmaceutical companies
- Patient enrollment began in Feb 2015
- Planned total enrollment: 4,500/2 years
GI-SCREEN
14
(as of April 1, 2016)
Center for Public Health Sciences
Groups
Divisions
Epidemiology
Prevention
Research
Screening
Research
Prevention
Screening Assessment and Management
Screening Technology and System Development
Director
Biostatistics
Common
Research
Health Sociology
 Clinical Economics
 Bioethics
Cancer
Control
Research
QOL Research
Some department names are not fixed yet
Cancer Control Research
Health Care Research
15
Center for Public Health Sciences
Improving the health as well as QOL of Japanese people by achieving
early detection & prevention of cancer, supporting cancer patients and
their families

Epidemiological Studies
 Accumulate evidence for better cancer survivorship and for better understanding of
disease cause from large-scale population-based cohort studies or any other
epidemiological studies
 Educate patients on evidence-based information in order to perform appropriate cancer
preventive routine day to day.

Research on Early Cancer Screening and its Prevention
 Develop risk assessment plan and cancer screening guidelines ASAP
 Increase the overall cancer screening tests and improve the evaluation capabilities of
screening results

Public Health Policy Research
 Accumulate various data and create action plan for cancer prevention, supportive care,
palliative care and how to return to social life
 Encourage most advanced and specialized research on cancer diagnosis and treatment
(as of July 1, 2016)
Center for Cancer Control & Information Services
Cancer Information Service
Medical Support and Partnership
Director
Cancer Survivorship Research
Health Services Research
Tobacco Policy Research
Center for Cancer Registries
17
Center for Cancer Control & Information Services
Established in October 2006
Provides correct cancer info. & supports to
promote standardizing hospital service nationwide
＜7 Core Functions＞
1. Cancer information Services
2. Cancer statistics & Analysis (Cancer
Registration)
3. Supporting for Cancer Diagnosis & Treatment
4. Training of Cancer Specialists
5. Cancer Survivorship Research
6. Cancer Health Services Research
7. Tobacco Policy Research
Providing information
Web-based &printed
information
Patients, families &general public
Consultation
Local Hospitals
Support
cooperation
Books and booklets
Website
427 Designated Cancer Care Hospitals（June 2016）
District Designated
Prefectural Designated
Cancer Care Hospitals
Cancer Care Hospitals
Cancer Care Cooperation
Support
Center
Cancer Care
Support
18
Center
NCC builds nation wide cancer-care
network as the center of the hospitals
National Cancer Center
Prefectural Designated Cancer Care Hosps--49
District Designated Cancer Care Hosps---349
Other designated hosps ---29
Build a clinical support system
for the Prefectural + District-Designated
427 Cancer Care Hospitals in Japan
都道府県がん診療連携拠点病院連絡協議会
臨床研究部会
がん登録部会
情報提供・相談支
援部会
緩和ケア部会
19
Center for Research Administration
and Support (CRAS)
(as of April 1, 2016)
Research Administration
Research Coordination
Director
Research Promotion
Biostatistics
 Regulatory Science
 Human Research Protection
 Bioethics
20
Center for Research Administration and Support (CRAS)
To provide more powerful and systematic research support based on the
“NCC New Vision”

Research Administration Division


Research Coordination Division


Planning and support of investigator initiated clinical trials in view of marketing approval
and the National Health Insurance pricing
Human Research Protection Section


Study planning, design, analysis, interpretation and statistical aspects of publications.
Regulatory Science Section


Data management and monitoring of clinical studies;
Coordination of multi-institutional clinical trials.
Biostatistics Division


Planning, management and coordination of clinical studies and CRC operation
Research Promotion Division


Various administrative works related to NCC research, grants and funding;
Research Administrator; research audit; alliance and intellectual properties.
Secretariats for ethical review board committees for human subject research.
Bioethics Section

Studies and Education on bioethical aspects of medical research.
21
NCC: Number of Publication and Citation
（１）Number of Publication and Citation（as of June 2016）
Year
Total Publication including Review
Articles（Articles Only）
Citation (Articles Only)
Impact Factor (Articles Only)
Source: Web of Science
2010
2011
2012
2013
2014
2015
Total
545(515)
550(527)
593(562)
620(574)
670(636)
660(611)
3,669(3,425)
14,701(13,548)
11,814(11,269)
9,896(9,372)
7,788(6,964)
3,808(3,440)
1,778(1,675)
42,758(46,268)
12(12)
12(12)
19(19)
17(16)
13(13)
23(22)
106(94)
（２）Comparison with Japanese Academia （2010/1/1 ～ 2015/12/31）
１）Overall Ranking
２）NCC’s HCP ranking
and Rate by Field
◯ NCC is ranked at 18 for HCP for22 fields(44 for publication and 24 for citation) and ４ among National Research and
Development Agency.
◯ NCC is ranked at 2 for relative ranking considering organization size
Total 22 Fields
High Citation Publication （HCP）
順位
機関名
Articles Only
2010-2015 (2006-2009)
# of HCP
（A)
１ Tokyo University
２ Kyoto University
３ Riken
４ Osaka University
５ Tohoku University
６ Nagoya University
７ NIMS
８ Kyushu University
９ AIST
１０ Tsukuba University
１１ Tokyo Industrial University
１２ Hiroshima University
１２ Waseda University
１４ Okayama University
１５ Hokkaido University
１６ Kobe University
１７ Shinshu University
１８ National Cancer Center
１８ KEK
２０ NIES
679
369
304
257
226
186
165
160
150
140
139
113
113
112
104
87
82
80
80
71
（324)
(179)
(178)
(147)
(132)
( 91)
( 47)
( 57)
(116)
( 63)
( 88)
( 39)
( 24)
( 36)
( 53)
( 40)
( 11)
( 32)
( 25)
( 13)
Relative Ranking considering
organization size
HCP rate
Total Budget
JPN 000M
1.49
1.11
2.23
0.98
0.87
1.03
2.09
0.86
1.14
1.20
1.00
1.16
1.67
1.36
0.59
1.02
1.68
2.30
2.35
3.42
805
548
516
437
456
316
120
417
639
407
216
249
90
184
362
206
137
61
197
117
Publication Rate vs
NCC Budget
0.64
0.51
0.45
0.45
0.38
0.45
1.05
0.29
0.18
0.26
0.49
0.35
0.96
0.46
0.22
0.32
0.46
1.00
0.31
0.46
Article Only 2006-2015
◯ NCC generate world leading
citation articles (top 1%) in
8 fields as below. NCC is
ranked #2 in clinical
research in Japan
Rank # of HCP HCP Rate
1 1,003
2
548
3
482
4
404
5
358
6
277
10
212
9
217
7
266
11
203
8
227
13
152
15
137
14
148
12
157
16
127
21
93
17
112
18
105
24
84
1.36
1.01
2.15
0.93
0.83
0.95
1.65
0.72
1.10
1.08
0.96
0.96
1.31
1.09
0.55
0.95
1.23
2.09
1.88
2.46
Field
# of R
HCP
HC an
Rate
P
k
67
2
2.51
Molecular
Biology
5
12
2.54
Social
Science
2
8
2.74
Biology
2
26
1.17
Immunol
ogy
Agricultu
re
1
22
1.18
1
6
5.88
CNS
1
23
1.27
Material
1
34
25.0
80
18
2.30
Clinical
Total
22
NCC is No.1 in Oncology Publication and Citation
①Publication（Recent６ years）
◯ No.1 in Oncology
◯ Top Tier in Total Clinical Medicine
field
②Citation（Recent 6 years）
◯ No. 1 in Oncology
◯ No. 4 in citation in Clinical Medicine
Field after Tokyo, Kyoto and
Osaka University
③HCP（recent 6 years）
◯ No. 1 in oncology
◯ No.2 in HCP in Clinical Medicine Field
after Tokyo University
No1 in Oncology
◯ NCC is No. 1 in terms of # of First
Author or Corresponding Author among
HCP
No1 in Oncology
No1 in Oncology
Top Rank in FA or CA
１．Source: Edited by NCC from Tomson Reuter’s “Essential Science Indicators（ESI）”
２．ESI is the public information released by Tomson Reuter to show top 1% citation list in 22 scientific fields every year. NCC edited the information so that NCC can be
compared with other Japanese institutes in the above figure. Consequently it is demonstrated that NCC continue to deliver HCP at the highest level regularly.
Tomson Reuter published the ranking of Japanese institutions based on comprehensive information including articles and reviews on April 18, 2016. The above information
is the edited results to exclude “Reviews”.
3. JST is excluded from ranking.
23